Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Eltrombopag for Continued Treatment
NCT01957176Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 4 trial of eltrombopag in immune thrombocytopenia (ITP), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01957176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01957176.